| Literature DB >> 1734950 |
J Skillings1, R Wierzbicki, E Eisenhauer, P Venner, F Letendre, D Stewart, B Weinerman.
Abstract
The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater than 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1734950 DOI： 10.1097/00002371-199201000-00008
Source DB: PubMed Journal: J Immunother (1991) ISSN： 1053-8550